Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:417106.
doi: 10.1155/2012/417106. Epub 2012 Dec 22.

Haemorrhagic colitis caused by dasatinib

Nishant Patodi  1 , Nidhi Sagar, Zbigniew Rudzki, Gerald Langman, Naveen Sharma
Affiliations

Haemorrhagic colitis caused by dasatinib

Nishant Patodi et al. Case Rep Hematol. 2012.

Abstract

Gastrointestinal bleeding appears to be a common adverse event associated with dasatinib therapy. Here we present a case of a 59-year-old man with chronic myeloid leukaemia (CML) developing the rarest complication of haemorrhagic colitis with dasatinib therapy which resolved rapidly after treatment withdrawal.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Endoscopic image of the sigmoid colon demonstrating deep ulceration with mucopurulent exudate.
Figure 2
Figure 2
(a) A diffuse inflammatory cell infiltrate is present in the lamina propria with cryptitis (H&E; ×40). (b) A crypt is distended by mucus and neutrophils while the lining colonocytes are focally attenuated (H&E; ×100).
Figure 3
Figure 3
Resolution of colonic ulceration following discontinuation of dasatinib.
See this image and copyright information in PMC

References

    1. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology. 2009;27(35):6041–6051. - PMC - PubMed
    1. Quintás-Cardama A, Kantarjian H, Ravandi F, et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer. 2009;115(11):2482–2490. - PMC - PubMed
    1. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. The New England Journal of Medicine. 2006;354(24):2531–2541. - PubMed
    1. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. Journal of Medicinal Chemistry. 2004;47(27):6658–6661. - PubMed
    1. Shieh MP, Mitsuhashi M, Lilly M. Moving on up: second-line agents as initial treatment for newly-diagnosed patients with chronic phase CML. Clinical Medicine Insights. 2011;5:185–199. - PMC - PubMed

LinkOut - more resources